Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2002 1
2003 2
2004 1
2005 2
2007 1
2010 3
2011 5
2012 14
2013 20
2014 26
2015 21
2016 28
2017 38
2018 23
2019 31
2020 87
2021 109
2022 131
2023 96
2024 59
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

607 results

Results by year

Filters applied: . Clear all
Page 1
Remdesivir for the Treatment of Covid-19 - Final Report.
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. Beigel JH, et al. Among authors: ohmagari n. N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8. N Engl J Med. 2020. PMID: 32445440 Free PMC article. Clinical Trial.
Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial.
Yotsuyanagi H, Ohmagari N, Doi Y, Yamato M, Bac NH, Cha BK, Imamura T, Sonoyama T, Ichihashi G, Sanaki T, Tsuge Y, Uehara T, Mukae H. Yotsuyanagi H, et al. Among authors: ohmagari n. JAMA Netw Open. 2024 Feb 5;7(2):e2354991. doi: 10.1001/jamanetworkopen.2023.54991. JAMA Netw Open. 2024. PMID: 38335000 Free PMC article. Clinical Trial.
Human Gut Microbiota and Its Metabolites Impact Immune Responses in COVID-19 and Its Complications.
Nagata N, Takeuchi T, Masuoka H, Aoki R, Ishikane M, Iwamoto N, Sugiyama M, Suda W, Nakanishi Y, Terada-Hirashima J, Kimura M, Nishijima T, Inooka H, Miyoshi-Akiyama T, Kojima Y, Shimokawa C, Hisaeda H, Zhang F, Yeoh YK, Ng SC, Uemura N, Itoi T, Mizokami M, Kawai T, Sugiyama H, Ohmagari N, Ohno H. Nagata N, et al. Among authors: ohmagari n. Gastroenterology. 2023 Feb;164(2):272-288. doi: 10.1053/j.gastro.2022.09.024. Epub 2022 Sep 23. Gastroenterology. 2023. PMID: 36155191 Free PMC article.
Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study.
Mukae H, Yotsuyanagi H, Ohmagari N, Doi Y, Sakaguchi H, Sonoyama T, Ichihashi G, Sanaki T, Baba K, Tsuge Y, Uehara T. Mukae H, et al. Among authors: ohmagari n. Clin Infect Dis. 2023 Apr 17;76(8):1403-1411. doi: 10.1093/cid/ciac933. Clin Infect Dis. 2023. PMID: 36477182 Free PMC article. Clinical Trial.
Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed.
Butler MS, Gigante V, Sati H, Paulin S, Al-Sulaiman L, Rex JH, Fernandes P, Arias CA, Paul M, Thwaites GE, Czaplewski L, Alm RA, Lienhardt C, Spigelman M, Silver LL, Ohmagari N, Kozlov R, Harbarth S, Beyer P. Butler MS, et al. Among authors: ohmagari n. Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0199121. doi: 10.1128/AAC.01991-21. Epub 2022 Jan 10. Antimicrob Agents Chemother. 2022. PMID: 35007139 Free PMC article. Review.
Population-level Metagenomics Uncovers Distinct Effects of Multiple Medications on the Human Gut Microbiome.
Nagata N, Nishijima S, Miyoshi-Akiyama T, Kojima Y, Kimura M, Aoki R, Ohsugi M, Ueki K, Miki K, Iwata E, Hayakawa K, Ohmagari N, Oka S, Mizokami M, Itoi T, Kawai T, Uemura N, Hattori M. Nagata N, et al. Among authors: ohmagari n. Gastroenterology. 2022 Oct;163(4):1038-1052. doi: 10.1053/j.gastro.2022.06.070. Epub 2022 Jul 2. Gastroenterology. 2022. PMID: 35788347 Free article.
Effectiveness of cefmetazole versus meropenem for invasive urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
Hayakawa K, Matsumura Y, Uemura K, Tsuzuki S, Sakurai A, Tanizaki R, Shinohara K, Hashimoto T, Hase R, Matono T, Kato H, Mawatari M, Hara H, Hamada Y, Saito S, Ohmagari N, Doi Y. Hayakawa K, et al. Among authors: ohmagari n. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0051023. doi: 10.1128/aac.00510-23. Epub 2023 Sep 13. Antimicrob Agents Chemother. 2023. PMID: 37702483 Free PMC article.
Dengue fever.
Kutsuna S, Ohmagari N. Kutsuna S, et al. Among authors: ohmagari n. Intern Med. 2014;53(15):1727. doi: 10.2169/internalmedicine.53.2652. Epub 2014 Aug 1. Intern Med. 2014. PMID: 25088899 Free article. No abstract available.
Infectious virus shedding duration reflects secretory IgA antibody response latency after SARS-CoV-2 infection.
Miyamoto S, Nishiyama T, Ueno A, Park H, Kanno T, Nakamura N, Ozono S, Aihara K, Takahashi K, Tsuchihashi Y, Ishikane M, Arashiro T, Saito S, Ainai A, Hirata Y, Iida S, Katano H, Tobiume M, Tokunaga K, Fujimoto T, Suzuki M, Nagashima M, Nakagawa H, Narita M, Kato Y, Igari H, Fujita K, Kato T, Hiyama K, Shindou K, Adachi T, Fukushima K, Nakamura-Uchiyama F, Hase R, Yoshimura Y, Yamato M, Nozaki Y, Ohmagari N, Suzuki M, Saito T, Iwami S, Suzuki T. Miyamoto S, et al. Among authors: ohmagari n. Proc Natl Acad Sci U S A. 2023 Dec 26;120(52):e2314808120. doi: 10.1073/pnas.2314808120. Epub 2023 Dec 22. Proc Natl Acad Sci U S A. 2023. PMID: 38134196 Free PMC article.
607 results